Sekeres, MA, Schoonen, WM, Kantarjian, H, List, A, Fryzek, J, Paquette, R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. Journal of the National Cancer Institute. 2008; 100(21):1542–1551.CrossRefGoogle ScholarPubMed

Rollison, DE, Howlader, N, Smith, MT, Strom, SS, Merritt, WD, Ries, LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1):45–52.CrossRefGoogle ScholarPubMed

Goldberg, SL, Chen, E, Corral, M, Guo, A, Mody-Patel, N, Pecora, AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28(17):2847–2852.Google Scholar

Pedersen-Bjergaard, J, Daugaard, G, Hansen, SW, Philip, P, Larsen, SO, Rorth, M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991; 338(8763):359–363.Google Scholar

Liew, E, Owen, C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011; 96(10):1536–1542.CrossRefGoogle ScholarPubMed

Hoffman, R. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009:xxvii, 2523.Google Scholar

Hsu, AP, Sampaio, EP, Khan, J, Calvo, KR, Lemieux, JE, Patel, SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011; 118(10):2653–2655.CrossRefGoogle ScholarPubMed

Bejar, R, Levine, R, Ebert, BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(5):504–515.Google Scholar

Walter, MJ, Shen, D, Ding, L, Shao, J, Koboldt, DC, Chen, K, et al. Clonal architecture of secondary acute myeloid leukemia. The New England Journal of Medicine. 2012; 366(12):1090–1098.CrossRefGoogle ScholarPubMed

Haase, D, Germing, U, Schanz, J, Pfeilstocker, M, Nosslinger, T, Hildebrandt, B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395.CrossRefGoogle ScholarPubMed

List, A, Dewald, G, Bennett, J, Giagounidis, A, Raza, A, Feldman, E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine. 2006; 355(14):1456–1465.CrossRefGoogle ScholarPubMed

Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar

Papaemmanuil, E, Gerstung, M, Malcovati, L, Tauro, S, Gundem, G, Van Loo, P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616–3627; quiz 99.Google Scholar

Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241–247.Google Scholar

Bejar, R, Stevenson, K, Abdel-Wahab, O, Galili, N, Nilsson, B, Garcia-Manero, G, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine. 2011; 364(26):2496–2506.Google Scholar

Yoshida, K, Sanada, M, Shiraishi, Y, Nowak, D, Nagata, Y, Yamamoto, R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64–69.CrossRefGoogle ScholarPubMed

Christiansen, DH, Andersen, MK, Pedersen-Bjergaard, J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001; 19(5):1405–1413.Google Scholar

Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016; 128(16):2096–2067.CrossRefGoogle ScholarPubMed

Valent, P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:485–491.Google ScholarPubMed

Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405.CrossRefGoogle Scholar

Bejar, R, Greenberg, PL. The impact of somatic and germline mutations in myelodysplastic syndromes and related disorders. Journal of the National Comprehensive Cancer Network. 2017; 15(1):131–135.Google Scholar

Network NCC. National Comprehensive Cancer Network Guidelines: Myelodysplatic Syndromes Version 2.2014 275 Commerce Drive, Suite 300, Fort Washington, PA 190342013 Version 2.2014: Available from: www.nccn.org.Google Scholar

Cargo, CA, Rowbotham, N, Evans, PA, Barrans, SL, Bowen, DT, Crouch, S, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362–2365.Google Scholar

Kwok, B, Hall, JM, Witte, JS, Xu, Y, Reddy, P, Lin, K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015; 126(21):2355–2361.CrossRefGoogle ScholarPubMed

Greenberg, P, Cox, C, LeBeau, MM, Fenaux, P, Morel, P, Sanz, G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079–2088.Google Scholar

Garcia-Manero, G, Shan, J, Faderl, S, Cortes, J, Ravandi, F, Borthakur, G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008; 22(3):538–543.CrossRefGoogle ScholarPubMed

Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar

Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454–2465.Google Scholar

Greenberg, PL, Stone, RM, Al-Kali, A, Barta, SK, Bejar, R, Bennett, JM, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(1):60–87.CrossRefGoogle ScholarPubMed

Hellstrom-Lindberg, E, Gulbrandsen, N, Lindberg, G, Ahlgren, T, Dahl, IM, Dybedal, I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003; 120(6):1037–1046.Google Scholar

Greenberg, PL, Sun, Z, Miller, KB, Bennett, JM, Tallman, MS, Dewald, G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114(12):2393–2400.CrossRefGoogle ScholarPubMed

Passweg, JR, Giagounidis, AA, Simcock, M, Aul, C, Dobbelstein, C, Stadler, M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(3):303–309.Google Scholar

Malcovati, L, Porta, MG, Pascutto, C, Invernizzi, R, Boni, M, Travaglino, E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005; 23(30):7594–7603.CrossRefGoogle ScholarPubMed

Cutler, CS, Lee, SJ, Greenberg, P, Deeg, HJ, Perez, WS, Anasetti, C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579–585.Google Scholar

Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013; 31(21):2662–2670.Google Scholar

Silverman, LR, Demakos, EP, Peterson, BL, Kornblith, AB, Holland, JC, Odchimar-Reissig, R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002; 20(10):2429–2440.CrossRefGoogle ScholarPubMed

Kadia, TM, Jabbour, E, Kantarjian, H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Seminars in Oncology. 2011; 38(5):682–692.CrossRefGoogle ScholarPubMed